Bladder cancer cells on a pink background

2026 ASCO Annual Meeting

Congress coverage by Medthority

Last updated: 31st May 2026

Published: 30th May 2026

Get closer to the conversations set to change clinical practice with our expert-led selection of key highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Find essential insights spanning second-line treatment strategies in small-cell lung cancer (SCLC) and first-line therapeutic options in non–small-cell lung cancer (NSCLC), alongside the latest trial data in bladder and prostate cancer.

ASCO 2026: CROWN study. Lorlatinib in ALK+ NSCLC

Explore 7-year CROWN data from ASCO 2026 showing durable lorlatinib benefit in ALK+ NSCLC, including long-term CNS control and safety outcomes.

READ NOW

ASCO 2026: HRQoL data from the KEYNOTE-905 trial

Explore KEYNOTE-905 data showing preserved HRQoL with perioperative EV plus pembrolizumab in cisplatin-ineligible MIBC.

READ NOW

ASCO 2026: TALAPRO-3: Talazoparib + enzalutamide in mCSPC

Phase 3 TALAPRO-3 results presented at ASCO 2026 show improved rPFS with talazoparib plus enzalutamide in HRR-altered mCSPC.

READ NOW

Lung Cancer Nexus

Browse expert insights on lung cancer

Photo of Prostate cancer cells under microscope, pink and purple tones.

Prostate Cancer Nexus

Congress coverage and expert podcasts

Light microscopy of the internal lining of the urinary bladder; haematoxylin and eosin stain

Managing High-Risk NMIBC

Expert and patient insights on high-risk NMIBC, including relevant clinical trial data and standout congress sessions.

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information

Name

Email address

Specialty

By providing your email address, you are opting in to receive our monthly newsletter.

Opt-in: By selecting this box, I consent to receiving marketing communications and information about Medthority's resources by email.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event